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ABSTRACT: Currently, polymer-based prefillable syringes are being promoted to the pharmaceutical market because they provide an
increased break resistance relative to traditionally used glass syringes. Despite this significant advantage, the possibility that barrel material
can affect the oligomeric state of the protein drug exists. The present study was designed to compare the effect of different syringe materials
and silicone oil lubrication on the protein aggregation. The stability of a recombinant fusion protein, abatacept (Orencia), and a fully human
recombinant immunoglobulin G1, adalimumab (Humira), was assessed in silicone oil-free (SOF) and silicone oil-lubricated 1-mL glass
syringes and polymer-based syringes in accelerated stress study. Samples were subjected to agitation stress, and soluble aggregate levels
were evaluated by size-exclusion chromatography and verified with analytical ultracentrifugation. In accordance with current regulatory
expectations, the amounts of subvisible particles resulting from agitation stress were estimated using resonant mass measurement and
dynamic flow-imaging analyses. The amount of aggregated protein and particle counts were similar between unlubricated polymer-based
and glass syringes. The most significant protein loss was observed for lubricated glass syringes. These results suggest that newly developed
SOF polymer-based syringes are capable of providing biopharmaceuticals with enhanced physical stability upon shipping and handling.
C© 2015 The Authors. Journal of Pharmaceutical Sciences published by Wiley Periodicals, Inc. and the American Pharmacists Association J
Pharm Sci 104:527–535, 2015
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INTRODUCTION
Pharmaceutical companies are increasingly using prefillable
syringes as an alternative to traditional vial packaging for the
delivery of injectable drug products. Significant advantages
of prefillable syringe systems over vial packaging include a
greater patient safety by reducing the risk of needle expo-
sure to pathogens when drawing solution from the vial, im-
proved dosing accuracy, and convenience for patient in terms
of product storage, administration, and disposal.1 The major-
ity of prefillable syringe systems available on the market are
made from glass. Glass syringes have a long history of use, and
have proven their performance and reliability among health-
care providers. Disadvantages associated with application of
glass-made syringe system include breakage, potential surface
reactivity, possibility of delaminated glass contamination, and
requirement of silicone oil lubrication. To overcome these prob-
lems, in recent years, polymer syringes mainly manufactured
from cyclic olefin polymer (COP) have been successfully de-
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veloped and are being promoted to the pharmaceutical mar-
ket. Polymer-based syringes have significant advantages of
increased break resistance, decreased surface reactivity, and
compatibility with the broad range of pH. In addition, by us-
ing a novel proprietary coating technique for plunger stopper,
polymer-based silicone oil-free (SOF) prefillable syringe system
has been developed.2 The potential disadvantages of polymer-
based syringes compared with glass syringes include higher
susceptibility to scratches, fair chemical resistance against
strong acids and alkalis, higher gas permeability, and rela-
tively short usage history. It should be mentioned though that
polymeric materials used to manufacture syringes utilized in
the present study have been extensively tested and have been
demonstrated to be safe and biocompatible materials for medi-
cal packaging application.3
For the therapeutic proteins, it is critically important that
the protein oligomeric state remains unchanged, as aggregates
and particles that can be composed of a protein alone or pro-
tein adsorbed onto foreign material are suspected to invoke
immunogenicity.4–9 During shipping and handling, liquid phar-
maceutical formulations are exposed to agitation that induces
aggregation and particle formation through protein interac-
tion with the interphases, such as air–solution and vial/syringe
surface–solution interphases.10,11 The factors which affect the
adsorption of protein to interfaces include protein proper-
ties, interface properties, and solution conditions. In the
present study, to elucidate independent and combined effects of
syringe barrel material, silicone oil lubrication, and differ-
ent formulation conditions on aggregation and/or particulate
formation, we placed two different pharmaceutical proteins,
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abatacept and adalimumab, formulated at two different pH,
into a 1.0-mL SOF and silicone oil-lubricated glass and
polymer-based syringes and subjected them to agitation stress
to reproduce conditions similar to those experienced by the
drug products during shipping. The resulting changes in the
soluble aggregates level were evaluated by size-exclusion chro-
matography (SEC). Because of the potential inaccuracies in
amounts of aggregates determined by SEC related to nonspe-
cific column adsorption,12 SEC results were verified with an-
alytical ultracentrifugation sedimentation velocity (AUC-SV),
which has been demonstrated as the most appropriate orthogo-
nal method to SEC.13,14 In accordance with the current regula-
tory expectations for the analysis of subvisible particles,15 res-
onant mass measurements (RMM) and dynamic flow-imaging
analyses were also performed to analyze particles in the range
of a few hundred nanometers to approximately hundred mi-
crometers. The evaluated aggregates and particles amounts
serve as a guideline to understanding the effects of different
syringe materials in the presence or absence of silicone oil lu-
brication on the stability of the pharmaceutical proteins.
MATERIALS AND METHODS
Materials
Silicone oil-free 1-mL polymer-based syringes (PLAJEXTM)
with long staked needle (27G), henceforth referred to as
“polymer-SOF,” were provided by Terumo Company (Tokyo,
Japan).2 PLAJEXTM syringe is a recently developed prefillable
syringe made from COP with a novel butyl rubber plunger
stopper coated using proprietary coating technique. Silicone
oil-lubricated PLAJEXTM syringes with an uncoated plunger
stopper, henceforth referred to as “polymer-so+,” were also pro-
vided by Terumo Company. SOF 1-mL borosilicate glass sy-
ringe barrels (conformed to the ISO 11040-4 standard), hence-
forth referred to as “glass-SOF,” and silicone oil-lubricated
1-mL glass syringes barrels (conformed to the ISO 11040-4
standard), henceforth referred to as “glass-so+,” were provided
by TOP Company (Tokyo, Japan). Glass syringes were used
with stainless steel needles and uncoated plunger stopper.
Abatacept (Orencia, molecular mass 92 kDa, pI = 4.5–5.516),
a recombinant fusion protein consisting of the extracellular
domain of human cytotoxic T-lymphocyte-associated antigen
4 (CTLA-4) linked to a modified Fc portion of human im-
munoglobulin G1 (IgG1), was purchased as a lyophilized pow-
der for intravenous infusion from Ono Pharmaceutical Com-
pany, Ltd. (Osaka, Japan) at a stock concentration of 250 mg.
Adalimumab (Humira, molecular mass 148 kDa, pI = 9.01 as
calculated using the SEDNTERP software), a recombinant fully
human IgG1 monoclonal antibody, was purchased from Eisai
Company, Ltd. (Tokyo, Japan). Gibco phosphate-buffered saline
(PBS), pH 7.4 (10×), was purchased from Life Technologies.




To elucidate the effect of formulation conditions on the levels
of aggregation/particles formation, two different buffers with
different pH were used in the present study. In our previous
studies of adalimumab stability against aggregation using a
number of formulations with different pH, we have detected
that agitation for 96 h induced noticeable aggregation in the
formulations with pH 4.0, 5.0, and 7.0 as indicated by an in-
crease in turbidity. Because of concerns that pH 4.0, which is
lower than that of stock formulation (pH 5.0) can result in the
unfolding of the protein, pH 5.0 and pH 7.4 were selected. For
abatacept, the same buffer conditions were chosen: pH 7.4 that
is similar to that of stock formulation (pH 7.2–7.8) and pH 5.0
that is close to abatacept pI value.
A vial containing 250 mg of lyophilized abatacept was re-
constituted with 10 mL of water for injections according to
the manufacturer’s instructions. First, sucrose was removed
by extensive dialysis against Millipore water for 24 h at 4◦C
with two water changes. The obtained solution was further dia-
lyzed into 1× PBS, pH 7.4, or 10 mM acetate buffer, pH 5.0 us-
ing slide-a-lyzer dialysis cassettes (MWCO 10,000 Da; Thermo
Fisher Scientific Inc., Waltham, MA) with two buffer exchanges
over 24 h at 4◦C. The adalimumab stock solution was buffer-
exchanged to 1× PBS, pH 7.4 trough gel filtration chromatog-
raphy using the AKTAprime plus HPLC system with HiLoadTM
16/60 SuperdexTM 200 prep grade column (GE Healthcare, Lit-
tle Chalfont, Buckinghamshire, United Kingdom). The level of
polysorbate 80 in the resulting solution was below quantifica-
tion limit of 0.001% as was confirmed using modified Dragen-
dorff reagent. A portion of the resulting solution was further
dialyzed to 10 mM acetate buffer at pH 5.0 using dialysis cas-
settes. Protein concentration was determined using UV absorp-
tion and no significant protein loss was confirmed.
The buffer-exchanged protein solutions were diluted to
1 mg/mL by a respective buffer and filtered through a 0.22-:m
polyvinylidene fluoride syringe filter (Millipore, Billerica, MA).
One milliliter of each protein solution formulated at either 1×
PBS or 10 mM acetate buffer was placed into 1-mL syringes,
leaving a headspace of 5 mm. Four different types of syringes
were used (three syringes of each type): (1) polymer-SOF; (2)
glass-SOF; (3) polymer-so+; and (4) glass-so+. To reproduce
the conditions experienced during shipping of therapeutic pro-
teins, syringes were subjected to shaking at 500 rounds/min
in a desktop orbital shaker Mix-VR (TAITEC Company Ltd.,
Saitama, Japan) at 4◦C for 1 week. The samples before stress
treatment were used as controls.
Absorbance and Transmission Measurements
Absorbance at 280 nm (A280) and transmission at 350 nm
(T350) of the samples were acquired using DU-500 UV/Visible
spectrophotometer (Beckman Coulter Inc., Brea, CA) and a
2-mL disposable cuvette with a cell length of 1 cm (Eppendorf,
Hamburg, Germany). Samples recovered from syringes were
centrifuged for 30 min at 15,600g, and percentage of insoluble
large aggregates was determined from the difference of A280
before and after centrifugation, taken as a percentage of the
A280 present before centrifugation.
High-Performance SEC
The samples were analyzed using the Alliance 1100 HPLC sys-
tem (Waters, Milford, MA), with simultaneous UV absorbance
detection at 215 and 280 nm with a TSK gel G3000SWXL col-
umn (Tosoh Bioscience, Tokyo, Japan) and 1× PBS pH 7.4 as
the mobile phase. Twenty microliter aliquot was injected into
the HPLC system. Flow rate was 0.5 mL/min, and elution time
was set at 30 min. High protein mass recovery (>98%) was
Krayukhina et al., JOURNAL OF PHARMACEUTICAL SCIENCES 104:527–535, 2015 DOI 10.1002/jps.24184
RESEARCH ARTICLE – Pharmaceutical Biotechnology 529
Table 1. Results of Percentage Transmission Measurements
Abatacept Adalimumab
Sample PBS Acetate Buffer PBS Acetate Buffer
Control 99.77 ± 0.23 99.54 ± 0.23 98.63 ± 0.23 98.63 ± 0.23
Polymer-SOF 97.72 ± 0.45 98.40 ± 0.23 98.40 ± 0.23 98.40 ± 0.00
Glass-SOF 99.08 ± 0.23 97.72 ± 0.45 97.05 ± 0.00 97.72 ± 0.23
Polymer-so+ 72.44 ± 0.17 39.36 ± 0.18 95.94 ± 0.22 93.97 ± 0.22
Glass-so+ 39.45 ± 0.18 14.72 ± 0.10 68.08 ± 0.47 60.26 ± 0.14
Data are shown as the average of three measurements ± standard deviation.
confirmed for all studied formulations, with the exception of
glass-so+, for which the recovery was about 85%.
Analytical Ultracentrifugation Sedimentation Velocity
The sedimentation velocity experiments were conducted using
ProteomeLab XL-I analytical ultracentrifuge (Beckman Coul-
ter) equipped with a 4-hole An60 Ti rotor. The experiments
were performed at 42,000 rpm at 20◦C using Beckman Coul-
ter 12-mm double-sector charcoal-filled epon centerpieces and
sapphire windows. Cells were aligned using an alignment tool
(Spin Analytical, Inc., Berwick, ME). Data were acquired using
an absorbance optical system at wavelengths of 280 nm (abata-
cept) or 292 nm (adalimumab). The scans were collected as fast
as possible between 6.0 and 7.2 cm from the axis of rotation
with the radial increment of 30 :m. Data were analyzed using
the C(s) method implemented in SEDFIT (version 14.1).17 The
partial specific volumes of abatacept and adalimumab were ob-
tained by using the program SEDNTERP 1.09 and were 0.7306
and 0.7282 cm3/g, respectively. The buffers viscosity and den-
sity were also calculated using SEDTERP and were 1.018 cP
and 1.0052 g/mL for PBS, and 1.004 cP and 0.9987 g/mL for
acetate buffer.
Resonant Mass Measurement
An Affinity Biosensors Archimedes system (Malvern Instru-
ments Limited,Malvern,Worcestershire, UnitedKingdom)was
equipped with a Hi-Q Micro Sensor and controlled by Particle-
Lab software. The sensor was flushed for 60 s with purified
water before the analysis. Subsequently, possible impurities in
the system were removed by two “sneeze” operations and the
system was flushed again for 60 s with purified water. The
sample solution was then loaded for 15 s. Before the analysis,
the limit of detection (LOD) was determined in automatic LOD
mode. Samples were analyzed for 300 s.
Microflow Imaging
Subvisible (micron sized) protein particles were counted us-
ing a microflow imaging (MFI) digital particle analyzer 4200
(Brightwell Technologies Inc., Ottawa, Canada). Prior to each
analysis, the system was primed with sufficient amount of Mil-
lipore water to obtain a particle-free baseline. Stressed samples
at 1 mg/mL were diluted, if necessary, 2–10× times with the re-
spective buffer, and volumes of 0.5 mL were analyzed at a flow
rate of 0.1 mL/min. The Protein Simple MFI View Analysis
Suite (MVAS) version 1.3 (Particle sizing Systems Japan Co.,
Ltd., Tokyo, Japan) was used for data analysis.
FlowCAM
Subvisible particles for the abatacept PBS formulation were
imaged using bench-top FlowCAM instrument (Fluid Imaging
Technologies, Scarborough, ME). Sample volumes of 0.2 mL
were analyzed at a flow rate of 0.08 mL/min. Flash duration
was set to 35.50 ms, and Camera Gain was set to 0. Visual-
Spreadsheet software version 3.4.8 (DKSH Japan K.K., Tokyo,
Japan) was used for data analysis.
RESULTS AND DISCUSSION
Quantification of Protein Aggregates
Results of percentage transmission measurements are sum-
marized in Table 1. Agitation stress caused decrease in trans-
mission at 350 nm in all samples, indicating the presence of
large aggregates. For either of the protein formulation, sam-
ples prefilled in SOF glass or polymer syringes had similar
relatively high percent transmission values, whereas samples
prefilled in silicone-lubricated syringe types had much lower
values.
For each type of syringe, amounts of insoluble aggregates
and soluble species were estimated (Table 2). The amounts of
insoluble aggregates were estimated by subtracting the amount
of protein in supernatant after centrifugation from total sam-
ple amount before stress testing. In agreement with percent-
age transmission measurements, amounts of insoluble aggre-
gates detected in SOF syringes were similar between glass
and polymer syringes irrespective of the sample and were
only slightly higher than those in control samples. Surface
of borosilicate glass is hydrophilic, whereas the COP plastic
surface is rather hydrophobic, suggesting that the difference
in surface hydrophobicity is insignificant for the aggregates
formation. In agreement with previous studies, the increased
loss of monomer was detected in silicone oil-lubricated com-
pared with SOF syringes.18 Because of the established sili-
cone oil sensitivity,19 abatacept samples prefilled in silicone oil-
lubricated syringes produced a substantial amount of insoluble
aggregates. The effect of silicone oil on insoluble aggregates for-
mation was more pronounced in case of silicone oil-lubricated
glass syringes comparedwith silicone oil-lubricated polymer sy-
ringes, with the exception of adalimumab formulated in acetate
buffer, for which no significant differences in insoluble aggre-
gates levels were observed between glass-so+ and polymer-so+
syringes.
Size-exclusion chromatography analysis was performed to
determine the fraction of soluble aggregates remaining af-
ter insoluble aggregates were removed by centrifugation at
15,600g for 30 min. For abatacept samples formulated in PBS,
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Table 2. Aggregates Quantification Results by SEC
Soluble Species (%)b
Sample Insoluble Aggregates (%)a Monomer Dimer Higher-Order Aggregates
Abatacept
PBS
Control <1 98.5 ± 0.1 1.5 ± 0.1 −
Polymer-SOF 2 98.4 ± 0.0 1.6 ± 0.0 −
Glass-SOF 2 98.4 ± 0.1 1.6 ± 0.1 −
Polymer-so+ 5 97.5 ± 0.3 1.6 ± 0.1 0.9 ± 0.1
Glass-so+ 7 91.4 ± 0.0 3.8 ± 0.0 4.8 ± 0.0
Acetate Buffer
Control 4 93.2 ± 0.0 6.8 ± 0.0 −
Polymer-SOF 4 88.5 ± 0.0 11.5 ± 0.0 −
Glass-SOF 4 90.9 ± 0.0 9.1 ± 0.0 −
Polymer-so+ 14 89.3 ± 0.1 10.7 ± 0.1 −
Glass-so+ 19 92.6 ± 0.0 7.4 ± 0.1 −
Adalimumab
PBS
Control <1 100.0 ± 0.0 − −
Polymer-SOF <1 100.0 ± 0.0 − −
Glass-SOF <1 99.9 ± 0.1 0.1 ± 0.1 −
Polymer-so+ <1 99.9 ± 0.1 0.1 ± 0.1 −
Glass-so+ 15 99.1 ± 0.1 0.5 ± 0.1 0.4 ± 0.1
Acetate Buffer
Control <1 100.0 ± 0.0 − −
Polymer-SOF <1 100.0 ± 0.0 − −
Glass-SOF <1 100.0 ± 0.0 − −
Polymer-so+ <1 100.0 ± 0.0 − −
Glass-so+ <1 99.3 ± 0.1 0.4 ± 0.0 0.3 ± 0.1
aStressed samples were centrifuged for 30 min at 15,600g, and percent insoluble aggregation was determined from the difference of A280 before and after
centrifugation, taken as a percentage of the A280 present before centrifugation.
bData are shown as the average of three measurements ± standard deviation.
the monomer fraction and aggregates levels were similar for
polymer-SOF and glass-SOF samples and were close to those
in the control sample. The fraction of monomer remaining in
the solution was considerably less in all abatacept samples
formulated in acetate buffer compared with PBS samples, con-
sistent with greater amounts of insoluble aggregates in ac-
etate buffer. Polymer-SOF, glass-SOF, and polymer-so+ adal-
imumab samples contained only monomers. In contrast, small
amounts of dimers and oligomers were detected by SEC for
silicone oil-lubricated glass syringe samples. Overall, similar
to insoluble aggregates, soluble aggregates levels detected in
silicone oil-lubricated glass syringes were higher than those in
silicone oil-lubricated polymer or SOF syringes, with the ex-
ception of glass-so+ abatacept sample formulated in acetate
buffer. For this sample, the recovery mass was estimated to
be approximately 82%, thus suggesting substantial adsorp-
tion of the aggregated protein to silica matrix of the SEC
column.20
To verify the performance of SEC analysis, aggregates were
also quantified by AUC-SV (Fig. 1). In general, there was a rea-
sonable agreement between SEC and AUC-SV results regard-
ing detected oligomeric species and their respective amounts
as reported previously.14 For the abatacept control, polymer-
SOF, and glass-SOF samples formulated in PBS, the esti-
mates of dimeric fractions obtained from AUC-SV (Fig. 1a)
were slightly lower than those obtained by SEC (Table 2). It
is assumed that these differences originate from reversibil-
ity of agitation-induced soluble aggregates: SEC analysis was
performed immediately following the completion of agitation,
whereas AUC-SV analysis was conducted on samples that have
been stored for a week at 4◦C after agitation completion. In
case of abatacept samples formulated in acetate buffer, lev-
els of aggregation determined by SEC using PBS as a mobile
phase were significantly lower than levels measured by AUC-
SV performed in acetate buffer (Suppl. Fig. S1). The differ-
ences in SEC and AUC-SV results can be attributed to the
sample dilution during the SEC analysis, which often causes
the dissociation of noncovalent aggregates. In agreement with
the results of previous studies, the levels of aggregates were
slightly higher when measured by AUC-SV compared with the
SEC estimates.13,21 The possibility also exists that the differ-
ences in the percentages of aggregates detected by SEC and
AUC-SV could be the consequence of change in noncovalent
aggregates distribution owing to the mobile phase composi-
tion (PBS), which is different from the sample formulation
(acetate buffer).22 In addition, discrepancy between SEC and
AUC-SV estimates can be a result of nonspecific interaction of
aggregates with the column caused by the combined effects
of the mobile and stationary phases, which leads to aggre-
gates filtration in the column, thus compromising the accuracy
of aggregates quantification.23 In fact, protein mass recovery
for polymer-so+ and glass-so+ abatacept samples formu-
lated in acetate buffer was slightly lower than that for PBS
formulations.
The quantitative results of AUC-SV were similar to those
obtained using SEC for both adalimumab formulations, with
the exception of sample formulated in acetate buffer and pre-
filled in glass-so+ syringe, for which the significant fraction of
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Figure 1. Aggregates quantification results by AUC-SV for the abatacept PBS formulation (a), abatacept acetate buffer formulation (b),
adalimumab PBS formulation (c), and adalimumab acetate buffer formulation (d).
oligomers was overlooked in SEC analysis. Overall, for both
protein formulations, the loss of monomer for samples in sil-
icone oil-lubricated syringes is clearly indicated by both SEC
and AUC-SV.
Quantification of Protein Particles
The results of particle counting obtained by RMM are shown
in Figure 2. On the basis of different buoyancy, protein parti-
cles and silicone oil droplets were discriminated and counted
separately.24 The experiments were performed using microsen-
sor, and the results of particle counting are shown in the range
of 0.5–2.0 :m. PBS-formulated abatacept samples showed sim-
ilar content of protein particles in polymer and glass SOF sy-
ringes, which were lower compared with samples in silicone
oil-lubricated syringes (Fig. 2a). In the abatacept acetate buffer
formulation, particle counts were similar between silicone oil-
lubricated and SOF syringes in the range 0.5–1.0 :m, however,
a substantial amount of larger particles was observed in the
silicone oil-lubricated syringes with the highest level of pro-
tein particles detected in glass-so+ syringes (Fig. 2b). Particle
counts were similar in control, polymer-SOF, and glass-SOF sy-
ringes for both adalimumab formulations (Figs. 2c and 2d). In
contrast, greater amounts of particles were detected for silicone
oil-lubricated syringes, and for adalimumab formulated in ac-
etate buffer, particles counts were higher in glass-so+ sample
than in other syringe types.
Concentrations of protein particles determined by MFI are
shown in Figure 3 and total particle counts are summarized
in Suppl. Tables S1 and S2. For each protein formulation,
the algorithm that allows discriminating silicone oil droplets
from total particle counts was developed. Samples from SOF
syringe filled with the protein formulation and silicone oil-
lubricated syringe filled with the respective formulation buffer
were subjected to MFI analysis to derive respective represen-
tative profiles of protein particles and silicone oil droplets. We
found that circularity is an appropriate parameter that can
be used to discriminate between protein particles and silicone
oil droplets. For each detected particle, the average circular-
ity value and its 95% confidence interval was obtained in the
size range from 1 to 10 :m. The mean values of the confi-
dence intervals for protein particles and silicone oil droplets
were used as a cutoff value (Suppl. Table S3). In the size range
above 10 :m, the recorded number of silicone oil droplet counts
was inappropriate for this approach. Therefore, to discriminate
protein particles from silicone oil droplets in the size range
above 10 :m, “Find Similar” option of MVAS 1.3 software was
utilized.
For the abatacept PBS formulation, particle concentrations
were similar for SOF polymer and glass syringe samples. Con-
siderably larger amounts of particles were detected for sil-
icone oil-lubricated syringes samples. The amount of large
particles was greater in glass-so+ than in any other syringe
type. In the abatacept acetate buffer formulation, similar par-
ticle counts were obtained for SOF syringes, and the highest
counts were obtained for the glass-so+ samples. In agreement
with MFI results for the abatacept, adalimumab formulations
showed similar particles concentrations for SOF syringes sam-
ples and higher levels of particles were detected for silicone
oil-lubricated samples.
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Figure 2. Results of particle counts by RMM for the abatacept PBS formulation (a), abatacept acetate buffer formulation (b), adalimumab PBS
formulation (c), and adalimumab acetate buffer formulation (d).
Figure 3. Concentrations of protein particles determined by MFI for the abatacept PBS formulation (a), abatacept acetate buffer formulation
(b), adalimumab PBS formulation (c), and adalimumab acetate buffer formulation (d).
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Figure 4. Representative FlowCAM images of protein particles obtained for the abatacept PBS formulation.
The loss of native protein upon particles formation is es-
sentially undetectable as cumulative mass of the protein in
particles only comprises a few micrograms.11 Nonetheless,
recent findings on aggregation behavior of keratinocyte growth
factor 2 during agitation have made it evident that particle
counting is much more sensitive measure of aggregation than
loss of soluble protein.25 As the RMM results (Fig. 2) and MFI
results (Fig. 3) did not demonstrate significant differences in
the particles counts for samples in SOF syringes, in the ab-
sence of silicone oil similar particle levels can be expected in
glass and polymer syringes.
Representative images of the protein particles detected by
FlowCAM in the abatacept PBS formulation in each different
type of syringe are shown in Figure 4 and Suppl. Figure S2.
The images obtained for protein particles from SOF syringes
are visually similar to each other, indicating the presence
of particles with sizes smaller than 60 :m. Images recorded
for polymer-so+ sample showed considerably larger particles
than in SOF samples. Even larger particles (with the largest
particle size of 130 :m), which morphologically appeared
as elongated fibrillar particles were observed in glass-so+
sample.
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One of the major concerns associated with the usage of
prefilled syringes is undesirable protein aggregation/particle
formation because of protein ability to adsorb to all types of
surfaces/interfaces. Layers of adsorbed protein form films that
are suspected to serve as a major source of protein particles
upon rupture.26 In the present study, the adsorption of protein
to the unlubricated glass surface could be attributed to charge–
charge effects, whereas in the case of unlubricated polymer,
protein could be adsorbed to the syringe surface mainly via
hydrophobic interactions. Agitation of protein solutions in the
presence of COP beads with no headspace did not induce ag-
gregate formation (data not shown). Thus, the disruption of the
layers of adsorbed protein followed by the release of the torn
film pieces into bulk solution phase can be attributed to the
air bubble in the headspace as suggested previously.11 An in-
crease in the particle counts upon agitation was detected in all
samples suggesting that the air bubble is a prerequisite for the
formation of protein particles.
Microflow imaging results indicated that at least with the
proteins and syringes used in the present study, no significant
differences in particle levels were observed between SOF glass
and polymer-based syringes.
Particle counts in samples from silicone oil-lubricated sy-
ringes were higher than those from SOF syringes, as confirmed
by both RMM and MFI results. This finding suggests that sil-
icone oil lubrication increases adsorption of the protein to the
surface, and/or accelerates disruption of the formed layer, which
leads to the increased particle formation. During agitation, the
dissociation of adsorbed protein from the surface was caused
by the air bubble, and after agitation completion the layers of
adsorbed protein were removed when the solution was pushed
through the syringe barrel with the plunger to collect samples
for the further analyses. In case of silicone oil-lubricated sy-
ringes, the particle counts were higher in glass-so+ than in
polymer-so+ syringes, indicating the stronger adsorption ca-
pacity of proteins used in this study to the silicone oil-lubricated
glass surface rather than polymer-based surface.
The results of MFI data analysis performed to discrimi-
nate protein particles from silicone oil droplets revealed that
higher protein particle counts detected by MFI in glass-so+
compared with polymer-so+ were associated with higher sili-
cone oil droplets counts in silicone oil-lubricated glass rather
than in polymer syringes (Suppl. Tables S4 and S5). Similarly,
the amount of insoluble aggregates was generally greater in
glass-so+ compared with polymer-so+ syringes. These results
suggest that a correlation exists between silicone oil levels and
amounts of particles formed in solution. In the present study,
the amount of silicon oil used to lubricate the inner surface
of syringe was about 0.7 mg per syringe for polymer-based and
1mg per syringe for glass syringe as claimed bymanufacturers.
Nonetheless, it is not clear whether higher silicone oil droplets
counts in glass-so+ rather than in polymer-so+ syringes were
simply the consequence of larger amount of silicone oil used for
syringe lubrication, or whether additional combined effects of
syringe barrel material and silicone oil lubrication could have
had an impact on particle formation. Further studies may be
needed to evaluate the effect of different silicone oil levels ap-
plied to the different syringe barrel material.
For both polymer-so+ and glass-so+, the abatacept acetate
buffer formulation showed larger amounts of particles than
those detected in PBS formulation (Suppl. Table S1). Similarly,
for adalimumab formulations prefilled in silicone oil-lubricated
syringes, amounts of particles were larger in acetate buffer for-
mulation compared with PBS formulation (Suppl. Table S2).
Interestingly, the increased protein particles counts in acetate
buffer formulation were consistent with higher amounts of sil-
icone oil droplets detected relative to PBS formulation, again
suggesting a positive correlation between the amount of sili-
cone oil droplets and particle counts. These observations in-
dicate that acetate buffer promotes detachment of silicone oil
droplets from the inner surface of syringe, which in turn leads
to increase in the number of particles. In case of the abatacept
(pI = 4.5–5.5), the differences in particle counts between ac-
etate buffer (pH 5.0) and PBS formulation (pH 7.4) were more
pronounced than for the adalimumab (pI = 9.01) formulations,
suggesting that formulations at pH near the isoelectric point
can favor the formation of aggregates and particles.
For the adalimumab solutions prefilled in SOF syringes, no
soluble aggregates were detected and particle counts were sim-
ilar for different formulations. However, in the adalimumab for-
mulations collected from glass-so+ syringes, soluble aggregates
were detected and particle counts were considerably higher
than in the other syringe types. This result suggests that a
correlation in the amount of aggregates detected by SEC/AUC-
SV and particle counts obtained by RMM/MFI can be present.
CONCLUSIONS
The effects of syringe material and silicone oil lubrication on
the levels of aggregation/particles formation were investigated
for the abatacept and adalimumab formulations at pH 5.0 and
7.4. In all cases, samples from SOF glass and polymer-based
syringes had similar amounts of insoluble aggregates, solu-
ble aggregates, and subvisible particles. Silicone oil lubrica-
tion caused the formation of insoluble aggregates in samples
other than the adalimumab formulated in acetate buffer, and
the effect was more pronounced in case of silicone oil-lubricated
glass syringes comparedwith silicone oil-lubricated polymer sy-
ringes. For both abatacept and adalimumab formulations, the
loss of monomer for samples in silicone oil-lubricated syringes
was confirmed by SEC and AUC-SV. Similarly, particle counts
in samples from silicone oil-lubricated syringes were higher
than those from SOF syringes, as confirmed by both RMM
and MFI results. For the same lubricated syringe type, particle
counts were higher in acetate buffer formulations than in PBS
formulations. The highest particles counts were consistently
observed in silicone oil-lubricated glass syringes, which was as-
sociated with larger silicone oil amounts detected in silicone
oil-lubricated glass syringes compared with polymer-based sy-
ringes. This study confirms that SOF polymer-based syringes
PLAJEXTM are capable of providing biopharmaceuticals with
enhanced physical stability upon shipping and handling.
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